STARD7 and glioblastoma: In this study, we established a seven-gene-based signature based on the diversity of genes, including protective (ZNF419, FOXG1, STARD7, and ZBTB16) and risk associated (CD180, SDK1, and CYP21A2) genes, which could classify IDH-wildtype GBM into low- and high-risk groups to distinguish between the clinical outcomes.